𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B

✍ Scribed by Jessica Tan; Anna S.F. Lok

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
69 KB
Volume
13
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Impact of the hepatitis B virus genotype
Impact of the hepatitis B virus genotype on pre– and post–liver transplantation outcomes
✍ Paul Gaglio; Sundeep Singh; Bulent Degertekin; Michael Ishitani; Munira Hussain; πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 144 KB πŸ‘ 1 views

Emerging data suggest that the hepatitis B virus (HBV) genotype and the precore and core promoter variants impact the outcome of orthotopic liver transplantation (OLT) for hepatitis B. The aim of this study was to determine if there is a correlation between HBV genotype, precore and core promoter va

Liver transplantation in Asian patients
Liver transplantation in Asian patients with chronic hepatitis B
✍ B. M. Ho; S. K. So; C. O. Esquivel; E. B. Keeffe πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 133 KB πŸ‘ 2 views

recurrence than patients with hepatitis D virus (HDV)-re-It has been suggested that Asian patients have related cirrhosis or patients with fulminant HBV infection. 3-5 duced survival after liver transplantation because of It has also been reported that the rate of HBV recurrence is greater recurrenc

Adefovir dipivoxil for wait-listed and p
Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results
✍ Eugene Schiff; Ching-Lung Lai; Stephanos Hadziyannis; Peter Neuhaus; Norah Terra πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 151 KB πŸ‘ 1 views

Wait-listed (n Ο­ 226) or post-liver transplantation (n Ο­ 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable

Prevention of hepatitis B recurrence aft
Prevention of hepatitis B recurrence after living donor liver transplantation: Primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy
✍ Shin Hwang; Sung-Gyu Lee; Chul-Soo Ahn; Ki-Hun Kim; Deok-Bog Moon; Tae-Yong Ha; πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 403 KB πŸ‘ 1 views

The prevention of hepatitis B virus (HBV) recurrence is essential after liver transplantation in patients infected with HBV. We evaluated the efficacy of primary high-dose hepatitis B immunoglobulin (HBIG) monotherapy and rescue antiviral therapy in 639 HBV-infected adult patients who underwent livi